Skip to main content
Clinical Trials/CTRI/2024/02/063138
CTRI/2024/02/063138
Not yet recruiting
Phase 3

Comparison of efficacy and safety of intralesional triamcinolone acetonide at different strength in treatment of alopecia areata: A Randomized Controlled Trial. - NI

Institute of Medical Sciences BH0 sites0 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Health Condition 1: L639- Alopecia areata, unspecified
Sponsor
Institute of Medical Sciences BH
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
Institute of Medical Sciences BH

Eligibility Criteria

Inclusion Criteria

  • 1\. All clinically diagnosed cases of alopecia areata with duration of illness more than 4 months.

Exclusion Criteria

  • 1\. Patients with existing skin diseases affecting the scalp such as psoriasis or seborrheic dermatitis.
  • 2\. Patients with evidence of adrenal cortex abnormality.
  • 3\. Patients known to be HIV or hepatitis B, C positive or otherwise immunocompromised

Outcomes

Primary Outcomes

Not specified

Similar Trials